<DOC>
	<DOCNO>NCT01630408</DOCNO>
	<brief_summary>This pilot feasibility study determine effect activate vitamin D compound ( paricalcitol ) heart structure ( size ) function ( ability relax ) patient normal kidney function form heart failure know HFPEF ( heart failure preserve ejection fraction ) . This study also examine heart failure-related hospitalization change cardiac-stretch biological marker believe change along heart size . Patients pilot study treat period 48 week paricalcitol dose previously approve FDA ( 1 mcg per day ) followed-up 4 week treatment complete .</brief_summary>
	<brief_title>The Effects Active VItamin D Left Atrial Volume Index</brief_title>
	<detailed_description>Heart failure ( HF ) among top ten cause hospitalization US . It estimate ~40-50 % patient HF preserve ejection fraction ( EF ) . Patients heart failure preserve ejection fraction ( HFPEF ) normal systolic function , impaired cardiac relaxation . The main cause HFPEF include left-ventricular hypertrophy ( LVH ) hypertension , hypertrophic cardiomyopathy , aortic stenosis normal EF , coronary artery disease restrictive cardiomyopathy . Only small clinical trial test therapeutic intervention patient HFPEF , produce either small negative effect . Relatively drug effect cardiac relaxation candidate chronic use , may significant side effect profile and/or inconvenient administer . Paricalcitol , FDA-approved activate form vitamin D , show slow LVH progression improve parameter associate diastolic function animal model ( see refs ) . Treatment paricalcitol also associate decrease cardiovascular morbidity mortality historical cohort study patient end-stage renal disease ( see refs ) . This single-center , single-arm , pilot study 20 patient HFPEF normal renal function stable medical therapy evaluate effect paricalcitol cardiac structure function .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Sign inform consent . Willing able adhere studyrelated procedure , include study medication regimen . ≥ 18 year old . Previous clinical diagnosis heart failure preserve ejection fraction : NYHA Class IIIV . Satisfy echocardiographic criterion within last year : Left ventricular ejection fraction ≥ 50 % , cardiac magnetic resonance ventriculogram ; Left atrial size ≥ 4 cm long axis &gt; 5.2 cm four chamber length ; Septal wall thickness &gt; 1.2 cm ( female ) 1.3 cm ( male ) ; Doppler evidence moderate severe diastolic dysfunction ( ≥ Grade II ) transmitral inflow , pulmonary venous flow , color Mmode and/or tissue Doppler ( per European Society Cardiology guideline ) . Experienced ≥ 1 follow last 12 month : Hospitalization acute heart failure ( primary diagnosis ) ; Long term treatment loop diuretic ; Mean pulmonary capillary wedge pressure ≥ 16 mm Hg catheterization dyspnea ; Left ventricular end diastolic pressure ( LVEDP ) ≥ 19 mm Hg catheterization dyspnea ; Acute treatment intravenous loop diuretic hemofiltration . On stable medical therapy last 30 day study entry ( defined change angiotensin convert enzyme inhibitor [ ACEI ] , angiotensin receptor blocker , aldosterone inhibitor , betablockers calcium channel blocker . Satisfy criterion initial lab screening : Estimated glomerular filtration rate ( eGFR ) ≥ 30 ml/min ; Corrected serum Ca 8.010.0 mg/dL ( 2.02.5 mmol/L ) ; Phos ≤ 5.2 mg/dL ( 1.68 mmol/L ) ; Serum albumin ≥ 3.0 g/dL ( 30 g/L ) ; Negative serum pregnancy test female childbearing potential ( within 2 week start study treatment ) . Women childbearing potential must practice barrier/oral contraception studyrelated treatment , surgically sterile one year postmenopausal , nonnursing nonpregnant . Taking &gt; 1,000 IU vitamin D preparation daily within last 30 day . Received activated vitamin D preparation include paricalcitol ( Zemplar® ) , doxercalciferol ( Hectorol® ) calcitriol ( Rocalctrol® , Calcijex® ) within last 90 day prior study entry . History nephrolithiasis . Poorly control hypertension ( systolic blood pressure &gt; 180 mmHg and/or diastolic blood pressure &gt; 110 mmHg Screening ; confirm repeat ) . Secondary hypertension ( i.e . renal artery stenosis , primary aldosteronism pheochromocytoma ) . Severe hepatic impairment . Use known inhibitor ( ie , ketoconazole ) inducer ( ie , carbamazepine ) cytochrome P450 3A ( CYP3A ) within 2 week prior take study drug . HIV positive . Condition prognosis &lt; 1 year study entry heart failure . Significant valvular disease define moderate severe aortic mitral stenosis , mitral aortic regurgitation . Infiltrative cardiac disease ( sarcoid , amyloid , hemochromatosis , lymphoma , etc. ) . Arrhythmogenic right ventricular cardiomyopathy . Active myocarditis . Constrictive restrictive pericarditis . Acute coronary artery disease symptom define emergency department visit hospital admission unstable angina , STelevation myocardial infarction ( STEMI ) , nonSTelevation myocardial infarction ( NSTEMI ) , percutaneous coronary intervention ( PCI ) coronary artery bypass graft ( CABG ) within 90 day study entry . Poor echocardiographic window . Current active treatment another investigational study participation another investigational study within 1 month screening . Active malignancy except situ carcinoma cervix , localize squamous basal cell carcinoma skin . Other serious concurrent recent medical psychiatric condition , Investigator 's opinion , make patient unsuitable participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Preserved ejection fraction</keyword>
	<keyword>Left ventricular hypertrophy</keyword>
	<keyword>Activated vitamin D</keyword>
	<keyword>Cardiac lusitropic effect</keyword>
	<keyword>Hospitalizations</keyword>
</DOC>